High-Sensitivity Troponin Highlights the Need for New Methods to Evaluate Diagnostic Tests

Research output: Contribution to journalEditorialResearchpeer-review

Abstract

[Extract] To be clinically useful, diagnostic tests need high precision. The original troponin assays had poor precision: they had high variability, particularly at the level used to determine whether a myocardial infarction (MI) was present. To address this problem, high-sensitivity troponin (hs Tn) assays were developed, the sensitivity referring not to the tests’ diagnostic sensitivity, but the analytic sensitivity with lower limits of detection and greater precision, including at the upper reference limit used to determine the presence of MI. This makes hs Tn more useful for ruling out MI and acute coronary syndrome in patients presenting with acute chest pain, allowing a greater proportion of patients to be discharged home earlier and potentially reducing the sex bias in the diagnosis of MI. These assays have been in use in Europe and Australasia since about 2010 but have only recently been approved by the Food and Drug Administration for clinical use in the United States.
Original languageEnglish
Article numbere004468
Number of pages4
JournalCirculation: Cardiovascular Quality and Outcomes
Volume11
Issue number2
DOIs
Publication statusPublished - Feb 2018

Cite this

@article{312dd3c771ea4a88bf5c991f820f3eb4,
title = "High-Sensitivity Troponin Highlights the Need for New Methods to Evaluate Diagnostic Tests",
abstract = "[Extract] To be clinically useful, diagnostic tests need high precision. The original troponin assays had poor precision: they had high variability, particularly at the level used to determine whether a myocardial infarction (MI) was present. To address this problem, high-sensitivity troponin (hs Tn) assays were developed, the sensitivity referring not to the tests’ diagnostic sensitivity, but the analytic sensitivity with lower limits of detection and greater precision, including at the upper reference limit used to determine the presence of MI. This makes hs Tn more useful for ruling out MI and acute coronary syndrome in patients presenting with acute chest pain, allowing a greater proportion of patients to be discharged home earlier and potentially reducing the sex bias in the diagnosis of MI. These assays have been in use in Europe and Australasia since about 2010 but have only recently been approved by the Food and Drug Administration for clinical use in the United States.",
author = "Jenny Doust and Paul Glasziou",
year = "2018",
month = "2",
doi = "10.1161/CIRCOUTCOMES.117.004468",
language = "English",
volume = "11",
journal = "Circulation: Cardiovascular Quality and Outcomes",
issn = "1941-7705",
publisher = "Lippincott Williams & Wilkins",
number = "2",

}

High-Sensitivity Troponin Highlights the Need for New Methods to Evaluate Diagnostic Tests. / Doust, Jenny; Glasziou, Paul.

In: Circulation: Cardiovascular Quality and Outcomes, Vol. 11, No. 2, e004468, 02.2018.

Research output: Contribution to journalEditorialResearchpeer-review

TY - JOUR

T1 - High-Sensitivity Troponin Highlights the Need for New Methods to Evaluate Diagnostic Tests

AU - Doust, Jenny

AU - Glasziou, Paul

PY - 2018/2

Y1 - 2018/2

N2 - [Extract] To be clinically useful, diagnostic tests need high precision. The original troponin assays had poor precision: they had high variability, particularly at the level used to determine whether a myocardial infarction (MI) was present. To address this problem, high-sensitivity troponin (hs Tn) assays were developed, the sensitivity referring not to the tests’ diagnostic sensitivity, but the analytic sensitivity with lower limits of detection and greater precision, including at the upper reference limit used to determine the presence of MI. This makes hs Tn more useful for ruling out MI and acute coronary syndrome in patients presenting with acute chest pain, allowing a greater proportion of patients to be discharged home earlier and potentially reducing the sex bias in the diagnosis of MI. These assays have been in use in Europe and Australasia since about 2010 but have only recently been approved by the Food and Drug Administration for clinical use in the United States.

AB - [Extract] To be clinically useful, diagnostic tests need high precision. The original troponin assays had poor precision: they had high variability, particularly at the level used to determine whether a myocardial infarction (MI) was present. To address this problem, high-sensitivity troponin (hs Tn) assays were developed, the sensitivity referring not to the tests’ diagnostic sensitivity, but the analytic sensitivity with lower limits of detection and greater precision, including at the upper reference limit used to determine the presence of MI. This makes hs Tn more useful for ruling out MI and acute coronary syndrome in patients presenting with acute chest pain, allowing a greater proportion of patients to be discharged home earlier and potentially reducing the sex bias in the diagnosis of MI. These assays have been in use in Europe and Australasia since about 2010 but have only recently been approved by the Food and Drug Administration for clinical use in the United States.

UR - http://www.scopus.com/inward/record.url?scp=85048416982&partnerID=8YFLogxK

U2 - 10.1161/CIRCOUTCOMES.117.004468

DO - 10.1161/CIRCOUTCOMES.117.004468

M3 - Editorial

VL - 11

JO - Circulation: Cardiovascular Quality and Outcomes

JF - Circulation: Cardiovascular Quality and Outcomes

SN - 1941-7705

IS - 2

M1 - e004468

ER -